Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary

Open access

Abstract

INTRODUCTION: In 1998, the first Japanese practice guidelines on osteoporosis was published. It has been updated several times, with the most recent being the full-scale 2011 edition and its abridged edition. The present guidelines provide information for the managements of primary osteoporosis in postmenopausal women and men over 50 years old, a summary of the evidence for the treatment of secondary osteoporosis, and a summary of the evidence for the prevention of osteoporosis in younger people. METHOD: The present Executive Summary is primarily based on the content of the 2011 Japanese abridged edition. One of the key changes is revision of the criteria for initiation of pharmacological treatment, along with an introduction of the fracture risk factors used in FRAX®. Key figures and tables were selected from the Japanese abridged edition and a reference list was added. RESULT AND CONCLUSIONS: The essential points of the Japanese practice guidelines on osteoporosis were translated into English for the first time. It is hoped that the content of the guidelines becomes known throughout the world.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11657-012-0109-9

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Estimated prevalence of osteoporosis in Japan. Osteoporosis was diagnosed from BMD at vertebrae L2–4 (a) and proximal femur (b). Data from Yoshimura [1] (Copyright© 2009 Springer Science + Business Media BV)
Fig. 1 Estimated prevalence of osteoporosis in Japan. Osteoporosis was diagnosed from BMD at vertebrae L2–4 (a) and proximal femur (b). Data from Yoshimura [1] (Copyright© 2009 Springer Science + Business Media BV)CC BY-NC · PubMed Central
Fig. 2 Factors causing deterioration of bone strength
Fig. 2 Factors causing deterioration of bone strengthCC BY-NC · PubMed Central
Fig. 3 Procedure for the diagnosis of osteoporosis. YAM young adult mean (20 to 44 years of age). Adapted from Orimo [4] (Copyright© 2001 Springer Science + Business Media BV)
Fig. 3 Procedure for the diagnosis of osteoporosis. YAM young adult mean (20 to 44 years of age). Adapted from Orimo [4] (Copyright© 2001 Springer Science + Business Media BV)CC BY-NC · PubMed Central
Fig. 4 Clinical presentation and prognosis of osteoporosis
Fig. 4 Clinical presentation and prognosis of osteoporosisCC BY-NC · PubMed Central
Fig. 5 Measurement of bone metabolic markers in drug treatment of osteoporosis. #1: in patients taking bisphosphonates, measure after stopping drug for at least 6 months, and in patients taking other osteoporosis drugs, measure after stopping drug for at least 1 month. #2: measure one type each of a resorption marker and formation marker. #3: excluding eldecalcitol. #4: in patients expected to be on long-term bisphosphonate therapy, measure bone resorption markers and BAP or P1NP. Nishizawa [6] (Copyright© 2012 Springer Science + Business Media BV)
Fig. 5 Measurement of bone metabolic markers in drug treatment of osteoporosis. #1: in patients taking bisphosphonates, measure after stopping drug for at least 6 months, and in patients taking other osteoporosis drugs, measure after stopping drug for at least 1 month. #2: measure one type each of a resorption marker and formation marker. #3: excluding eldecalcitol. #4: in patients expected to be on long-term bisphosphonate therapy, measure bone resorption markers and BAP or P1NP. Nishizawa [6] (Copyright© 2012 Springer Science + Business Media BV)CC BY-NC · PubMed Central
Fig. 6 Diagnostic criteria for primary osteoporosis (updated in 2000). Primary osteoporosis is diagnosed according to these criteria in the absence of diseases causing low bone mass or secondary osteoporosis. #1: fragility fracture is a nontraumatic bone fracture that is caused by slight external force to a bone with low BMD (BMD less then 80 % of YAM). Sites of fracture include the spine, proximal femur, and the distal end of the radius. #2: BMD usually refers to lumbar BMD. However, when the measurement is inappropriate for reasons such as spinal deformity, the proximal femur BMD should be used. When measurement at those sites is difficult, BMD of the radius, second metacarpal bone, or calcaneus will be used. Revision of additional T-scores is under consideration. Adapted from Orimo [4] (Copyright © 2001 Springer Science + Business Media BV)
Fig. 6 Diagnostic criteria for primary osteoporosis (updated in 2000). Primary osteoporosis is diagnosed according to these criteria in the absence of diseases causing low bone mass or secondary osteoporosis. #1: fragility fracture is a nontraumatic bone fracture that is caused by slight external force to a bone with low BMD (BMD less then 80 % of YAM). Sites of fracture include the spine, proximal femur, and the distal end of the radius. #2: BMD usually refers to lumbar BMD. However, when the measurement is inappropriate for reasons such as spinal deformity, the proximal femur BMD should be used. When measurement at those sites is difficult, BMD of the radius, second metacarpal bone, or calcaneus will be used. Revision of additional T-scores is under consideration. Adapted from Orimo [4] (Copyright © 2001 Springer Science + Business Media BV)CC BY-NC · PubMed Central
Fig. 7 Criteria for osteoporosis screening. Risk factors for osteoporosis: non-modifiable factors: aging, sex (female), race, family history, late menarche, early menopause, and history of fracture. Modifiable factors: deficiency of calcium, vitamin D, and K; excess intake of phosphorus and salt; excessive calorie restriction; low BMI; lack of physical activity and sunlight; smoking; and excess intake of alcohol and coffee Orimo [8]
Fig. 7 Criteria for osteoporosis screening. Risk factors for osteoporosis: non-modifiable factors: aging, sex (female), race, family history, late menarche, early menopause, and history of fracture. Modifiable factors: deficiency of calcium, vitamin D, and K; excess intake of phosphorus and salt; excessive calorie restriction; low BMI; lack of physical activity and sunlight; smoking; and excess intake of alcohol and coffee Orimo [8]CC BY-NC · PubMed Central
Fig. 8 Criteria for initiation of pharmacological treatment. #1: this means proximal femoral fracture and/or vertebral fracture caused by slight external force after menopause in women and after age 50 in men. #2: this means distal forearm, proximal humerus, pelvis, lower leg and/or rib fracture caused by slight external force after menopause in women and after age 50 in men. #3: revision of additional T-scores is under consideration for some measurement sites. #4: this should be applied in persons <75 years. Additionally, a lower cutoff value does not include all young persons in and around their 50s for whom pharmacological treatment is recommended based on the present diagnostic criteria. #5: as these criteria refer to primary osteoporosis, they should not be applied to persons whose FRAX® risk factors are “glucocorticoid”, “rheumatoid arthritis”, or “secondary osteoporosis”. That is, these criteria should be applied only in persons who answer “No” to each of these items
Fig. 8 Criteria for initiation of pharmacological treatment. #1: this means proximal femoral fracture and/or vertebral fracture caused by slight external force after menopause in women and after age 50 in men. #2: this means distal forearm, proximal humerus, pelvis, lower leg and/or rib fracture caused by slight external force after menopause in women and after age 50 in men. #3: revision of additional T-scores is under consideration for some measurement sites. #4: this should be applied in persons <75 years. Additionally, a lower cutoff value does not include all young persons in and around their 50s for whom pharmacological treatment is recommended based on the present diagnostic criteria. #5: as these criteria refer to primary osteoporosis, they should not be applied to persons whose FRAX® risk factors are “glucocorticoid”, “rheumatoid arthritis”, or “secondary osteoporosis”. That is, these criteria should be applied only in persons who answer “No” to each of these itemsCC BY-NC · PubMed Central
Fig. 9 Meta-analyses on the efficacy of vitamin D. a Relative risk for vertebral fractures after treatment with vitamin D. RR relative risk, CI confidence interval. Open rhombus indicates using calcitriol and closed rhombus using alfacalcidol. Adapted from Papadimitropoulos [10] (Copyright© 2002 The Endocrine Society). b Compared risk of falling between vitamin D-treated group and control group. OR odds ratio, CI confidence interval. Adapted from Bischoff-Ferrari [11] (Copyright© 2004 American Medical Association)
Fig. 9 Meta-analyses on the efficacy of vitamin D. a Relative risk for vertebral fractures after treatment with vitamin D. RR relative risk, CI confidence interval. Open rhombus indicates using calcitriol and closed rhombus using alfacalcidol. Adapted from Papadimitropoulos [10] (Copyright© 2002 The Endocrine Society). b Compared risk of falling between vitamin D-treated group and control group. OR odds ratio, CI confidence interval. Adapted from Bischoff-Ferrari [11] (Copyright© 2004 American Medical Association)CC BY-NC · PubMed Central
Fig. 10 Effect of eldecalcitol compared with alfacalcidol. a Change in lumbar BMD. Data are mean ± SE, *p < 0.001 vs alfacalcidol group by Student t test (Matsumoto [12] (Copyright© 2011 Elsevier)). b Incidence of vertebral fracture. Hazard ratio (HR) is 0.74 and 95 % confidence interval (CI) is 0.56–0.97. Data from Matsumoto [12] (Copyright© 2011 Elsevier). c Incidence of non-vertebral fractures. HR for three major non-vertebral fractures is 0.52 and 95 % CI is 0.29–0.93, p = 0.031. Three major non-vertebral sites mean humerus, wrist, and hip, i.e., the three sites of major non-vertebral fractures recognized as osteoporotic fractures in FRAX®. HR for wrist fractures is 0.29 and 95 % CI is 0.11–0.77, p = 0.005. Data from Matsumoto [12] (Copyright© 2011 Elsevier) and the website of Pharmaceuticals and Medical Devices Agency (in Japanese)
Fig. 10 Effect of eldecalcitol compared with alfacalcidol. a Change in lumbar BMD. Data are mean ± SE, *p < 0.001 vs alfacalcidol group by Student t test (Matsumoto [12] (Copyright© 2011 Elsevier)). b Incidence of vertebral fracture. Hazard ratio (HR) is 0.74 and 95 % confidence interval (CI) is 0.56–0.97. Data from Matsumoto [12] (Copyright© 2011 Elsevier). c Incidence of non-vertebral fractures. HR for three major non-vertebral fractures is 0.52 and 95 % CI is 0.29–0.93, p = 0.031. Three major non-vertebral sites mean humerus, wrist, and hip, i.e., the three sites of major non-vertebral fractures recognized as osteoporotic fractures in FRAX®. HR for wrist fractures is 0.29 and 95 % CI is 0.11–0.77, p = 0.005. Data from Matsumoto [12] (Copyright© 2011 Elsevier) and the website of Pharmaceuticals and Medical Devices Agency (in Japanese)CC BY-NC · PubMed Central
Fig. 11 Meta-analysis on the efficacy of menatetrenone on fractures. OR odds ratio, CI confidence interval (Cockayne [13] (Copyright© 2006 American Medical Association))
Fig. 11 Meta-analysis on the efficacy of menatetrenone on fractures. OR odds ratio, CI confidence interval (Cockayne [13] (Copyright© 2006 American Medical Association))CC BY-NC · PubMed Central
Fig. 12 Effect of minodronic acid on BMD and vertebral fracture. a Percent change in lumbar spine and total hip BMD. Solid line is minodronic acid 1 mg (n = 134) and broken line is alendronate 5 mg (n = 135). Data are mean ± SE (Hagino [14] (Copyright© 2009 Elsevier)). b Incidence of vertebral fracture. Solid line is minodronic acid (n = 339) and broken line is placebo (n = 328). Relative risk is 0.411 (95 % confidence interval 0.267–0.634) by Cox regression model. *p < 0.0001 by log-rank test between the groups (Matsumoto [15] (Copyright© 2009 Springer Science + Business Media BV))
Fig. 12 Effect of minodronic acid on BMD and vertebral fracture. a Percent change in lumbar spine and total hip BMD. Solid line is minodronic acid 1 mg (n = 134) and broken line is alendronate 5 mg (n = 135). Data are mean ± SE (Hagino [14] (Copyright© 2009 Elsevier)). b Incidence of vertebral fracture. Solid line is minodronic acid (n = 339) and broken line is placebo (n = 328). Relative risk is 0.411 (95 % confidence interval 0.267–0.634) by Cox regression model. *p < 0.0001 by log-rank test between the groups (Matsumoto [15] (Copyright© 2009 Springer Science + Business Media BV))CC BY-NC · PubMed Central
Fig. 13 Effect of elcatonin on BMD and pain associated with vertebral fracture. a Percent change in lumbar spine BMD. Solid line is elcatonin (20 units per week) with 0.6 g calcium lactate and broken line is control (calcium lactate only). Data are mean ± SE. Numerals in parentheses denote number of patients. Comparison within groups: Student’s paired t-test, #p < 0.05; between groups: Student’s unpaired t-test, *p < 0.05. Orimo H [16] (Copyright© 1996 Springer Science + Business Media BV). b Percent change in pain associated with getting up evaluated with visual analog scale (VAS). Solid line is elcatonin (20 units per week, n = 44) and broken line is control (untreated, n = 42). Two-way repeated-measures ANOVA, *p < 0.05, **p < 0.01, NS not significant. Mann–Whitney U test, #p < 0.05, ##p < 0.01 (Nakano [17])
Fig. 13 Effect of elcatonin on BMD and pain associated with vertebral fracture. a Percent change in lumbar spine BMD. Solid line is elcatonin (20 units per week) with 0.6 g calcium lactate and broken line is control (calcium lactate only). Data are mean ± SE. Numerals in parentheses denote number of patients. Comparison within groups: Student’s paired t-test, #p < 0.05; between groups: Student’s unpaired t-test, *p < 0.05. Orimo H [16] (Copyright© 1996 Springer Science + Business Media BV). b Percent change in pain associated with getting up evaluated with visual analog scale (VAS). Solid line is elcatonin (20 units per week, n = 44) and broken line is control (untreated, n = 42). Two-way repeated-measures ANOVA, *p < 0.05, **p < 0.01, NS not significant. Mann–Whitney U test, #p < 0.05, ##p < 0.01 (Nakano [17])CC BY-NC · PubMed Central
Fig. 14 Efficacy of combination therapy with alendronate and active vitamin D3 on vertebral fracture. HR hazard ratio of incident vertebral fracture, CI confidence interval (Orimo [18] (Copyright© 2011 Informa Plc.))
Fig. 14 Efficacy of combination therapy with alendronate and active vitamin D3 on vertebral fracture. HR hazard ratio of incident vertebral fracture, CI confidence interval (Orimo [18] (Copyright© 2011 Informa Plc.))CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 3

  1. You K (2011) Osteoporos Jpn 19:626, in Japanese
  2. Orimo H, Hosoi T, Fukunaga M (eds) (2009) Manual for osteoporosis screening and health guidance. Life Science Publishing, Tokyo, in Japanese
  3. Nakano T (2011) Clinical effect of calcitonin (elcatonin) on acute pain for osteoporotic vertebral fracture: semi blind randomized controlled trial. Osteoporos Jpn 19:279

Cited by

See all 358

Metadata

Authors
Orimo, H., Nakamura, T., Hosoi, T., Iki, M., Uenishi, K., Endo, N., Ohta, H., Shiraki, M., Sugimoto, T., Suzuki, T., Soen, S., Nishizawa, Y., Hagino, H., Fukunaga, M., & Fujiwara, S.
Affiliations
  • Japan Osteoporosis Foundation (JP)
  • University of Occupational and Environmental Health Japan (JP)
  • National Center for Geriatrics and Gerontology (JP)
  • Kindai University (JP)
  • Japan Nutrition University (JP)
  • Niigata University (JP)
  • Sanno Medical Center (JP)
  • Research Institute and Practice for Involutional Diseases (JP)
  • Shimane University (JP)
  • Research Institute, National Center for Geriatrics and Gerontology (JP)
  • Tottori University (JP)
  • Kawasaki Medical School (JP)
  • Radiation Effects Research Foundation (JP)
Corresponding author
Hosoi, Takayuki
Venue
Archives of Osteoporosis
Published
2012-12
Volume
7
Issue
1-2
Pages
3-20
ISSN
  • 1862-3514 (ISSN-L)
  • 1862-3522
OpenAlex
W2030203316
Cited by
358
References
15
Citations by year
2026: 12 · 2025: 19 · 2024: 27 · 2023: 22 · 2022: 27 · 2021: 35 · 2020: 34 · 2019: 28 · 2018: 32 · 2017: 33 · 2016: 38 · 2015: 22 · 2014: 14 · 2013: 13 · 2012: 2
FWCI
17.43
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Archives of Osteoporosis (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
osteoporosis, osteoporosis prevention, osteoporosis treatment, postmenopausal women, men over 50, secondary osteoporosis, fracture risk assessment, FRAX, Japanese clinical practice guidelines
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Japan, Male, Middle Aged, Osteoporosis, Risk Factors, Incidence, Practice Guidelines as Topic, Age Distribution, Sex Distribution, Antirheumatic Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. https://app.cochat.ai/papers/10.1007/s11657-012-0109-9
The paper
Orimo, H., Nakamura, T., Hosoi, T., Iki, M., Uenishi, K., Endo, N., Ohta, H., Shiraki, M., Sugimoto, T., Suzuki, T., Soen, S., Nishizawa, Y., Hagino, H., Fukunaga, M., & Fujiwara, S. (2012). Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Archives of Osteoporosis. https://doi.org/10.1007/s11657-012-0109-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.